Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Golden Age Health Secures Exclusive Rights to Innostellar’s Gene Therapy LX-101 in China

Fineline Cube Jul 15, 2025

Singapore-based Golden Age Health, a specialty pharmaceutical company focused on rare and specialty diseases, has...

Company Drug

Merck Initiates EXPrESSIVE Phase III Trial for Once-Monthly HIV PrEP Drug MK-8527

Fineline Cube Jul 15, 2025

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) announced the initiation of the EXPrESSIVE Phase...

Company Drug

China Medical System’s CMS-D001 Gains NMPA Approval for Atopic Dermatitis Trials

Fineline Cube Jul 15, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) announced that it has received clinical trial...

Policy / Regulatory

NHSA Reports 2024 Healthcare Stats: BMI Fund Reaches RMB 3.49 Trillion Income with 95% Participation Rate

Fineline Cube Jul 15, 2025

The National Healthcare Security Administration (NHSA) this week released its national medical and healthcare development...

Company Drug

SinoMab BioScience Voluntarily Withdraws BLA for Suciraslimab in China Citing Need for Additional Data

Fineline Cube Jul 15, 2025

SinoMab BioScience Ltd (HKG: 3681) announced the voluntary withdrawal of its Biologics License Application (BLA)...

Company Deals

Mabwell Signs Licensing Agreement with Unilab for Denosumab Biosimilars in the Philippines

Fineline Cube Jul 15, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with Unilab, Inc.,...

Company Deals

Innovent Biologics and JD Health Form Strategic Partnership to Enhance Drug Supply and Healthcare Services

Fineline Cube Jul 15, 2025

China-based Innovent Biologics Inc., (HKG: 1801) and JD Health International Inc., (HKG: 6618) have officially...

Company Drug

Shanghai Henlius Biotech Initiates US Patient Dosing in Phase III Trial for HER2-Positive Gastric Cancer

Fineline Cube Jul 15, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) announced the first patient dosing in the US...

Company Drug

Bayer AG’s Kerendia Approved by FDA to Treat Adult Heart Failure with Ejection Fraction ≥40%

Fineline Cube Jul 15, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from...

Company Drug

Sichuan Biokin’s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma

Fineline Cube Jul 15, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Deals

Hunan Mabgeek Biotech Files for Hong Kong IPO to Expand Innovative Biologics Pipeline

Fineline Cube Jul 15, 2025

China-based Hunan Mabgeek Biotech Co., Ltd has submitted an application to the Hong Kong Stock...

Company Drug

GSK’s Arexvy RSV Vaccine Expansion for Adults 18-49 Receives FDA Review

Fineline Cube Jul 15, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has...

Others

Dizal’s Sunvozertinib Included in NCCN Guidelines for EGFR Exon20ins NSCLC Treatment

Fineline Cube Jul 14, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the inclusion of its sunvozertinib (trade name:...

Company Drug

Boao Super Hospital Introduces Xiaflex for Non-Surgical Peyronie’s Disease Treatment

Fineline Cube Jul 14, 2025

Boao Super Hospital in Hainan last week successfully introduced Xiaflex (collagenase clostridium histolyticum), a nonsurgical...

Company Deals

Lexenpharm Partners with AptarGroup for Single-Dose Nasal Spray Services in Greater China

Fineline Cube Jul 14, 2025

China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global...

Company Deals Drug

Eolas Therapeutics Gains Full Rights to AZD4041 for Opioid Use Disorder Development

Fineline Cube Jul 14, 2025

US-based Eolas Therapeutics has entered into an agreement with its UK partner AstraZeneca (AZ, NASDAQ:...

Company Deals

Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease

Fineline Cube Jul 14, 2025

Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late...

Company Drug

YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study

Fineline Cube Jul 14, 2025

Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...

Company Legal / IP

CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings

Fineline Cube Jul 14, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a favorable outcome in the opposition proceedings...

Others

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China

Fineline Cube Jul 14, 2025

Japan-based Eisai (TYO: 4523) announced the official commercial release of the first batch of its...

Posts pagination

1 … 122 123 124 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.